CMS certification 050625
Cedars-Sinai Medical Center
8700 Beverly Blvd, Los Angeles, CA 90048
Cedars-Sinai Medical Center has a CMS overall rating of 5 out of 5 stars. 78% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 14 and worse on 3. Emergency patients spend a median of 5 h 55 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 1,081 completed surveys, 20% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as very high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | CA | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 380 visits sampled · US median for EDs of the same volume: 3 h 21 min | 5 h 55 min | 2 h 54 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 16 visits sampled | 6 h 20 min | 4 h 20 min | 4 h 17 min |
| Left before being seen Lower is better · 97,510 patients | 9% | 2% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 1,854 patients | 64% | 70% | 65% |
How Cedars-Sinai Medical Center compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| Cedars-Sinai Medical CenterThis hospital | 5/5 | 78% | 5 h 55 min | 14 better 3 worse |
| Martin Luther King, Jr. Community HospitalSame city | 4/5 | 68% | 2 h 30 min | 3 better 1 worse |
| Docs Surgical HospitalSame city | Not rated | 72% | — | No different |
| Kaiser Foundation Hospital - West LaSame city | 3/5 | 73% | — | 1 better 1 worse |
| Adventist Health White MemorialSame city | 3/5 | 64% | 3 h 19 min | 2 better 1 worse |
| Keck Hospital of USCSame city | 5/5 | 82% | — | 5 better 1 worse |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Los Angeles.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 9,504 cases | Too few cases | 2.3% | 3.9% |
| Heart attack 409 cases | Too few cases | 8.3% | 11.9% |
| Heart failure 1,544 cases | Too few cases | 5.5% | 11.1% |
| Pneumonia 1,742 cases | Too few cases | 9.5% | 15.2% |
| Stroke 549 cases | Too few cases | 11.6% | 11.9% |
| COPD 191 cases | Too few cases | 5.9% | 8.6% |
| Heart bypass surgery (CABG) 223 cases | Too few cases | 1.7% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 1.06 likely 0.92 – 1.2 | 1 |
| After hip or knee replacement 472 cases | Too few cases | 3.1% | 4.1% |
| Deaths after a serious but treatable surgical complication 557 cases | Better | 134.15 per 1,000 likely 109.33 per 1,000 – 158.98 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 27,865 cases | No different | 0.75 per 1,000 likely 0.47 per 1,000 – 1.03 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 29,170 cases | No different | 0.14 per 1,000 likely 0 per 1,000 – 0.28 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 31,661 cases | No different | 0.19 per 1,000 likely 0.05 per 1,000 – 0.32 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 10,075 cases | No different | 2.05 per 1,000 likely 1.24 per 1,000 – 2.86 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 6,024 cases | No different | 1.38 per 1,000 likely 0.47 per 1,000 – 2.29 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 6,012 cases | No different | 8.2 per 1,000 likely 5.76 per 1,000 – 10.65 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 11,199 cases | No different | 4.1 per 1,000 likely 3.06 per 1,000 – 5.14 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 6,132 cases | Worse | 7.77 per 1,000 likely 6.11 per 1,000 – 9.44 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 2,803 cases | No different | 1.91 per 1,000 likely 0.72 per 1,000 – 3.11 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 8,257 cases | No different | 0.66 per 1,000 likely 0.06 per 1,000 – 1.25 per 1,000 | 1.06 per 1,000 |
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | Better | 0.66 likely 0.48 – 0.89 | 1 |
| Urinary tract infections from catheters (CAUTI) | Better | 0.39 likely 0.26 – 0.56 | 1 |
| Surgical site infections after colon surgery | No different | 1.17 likely 0.71 – 1.81 | 1 |
| Surgical site infections after abdominal hysterectomy | No different | 1.44 likely 0.37 – 3.91 | 1 |
| MRSA bloodstream infections | Better | 0.5 likely 0.27 – 0.86 | 1 |
| C. diff intestinal infections | Better | 0.63 likely 0.52 – 0.76 | 1 |
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 492 cases | Too few cases | 13.9% | 14.4% |
| Readmitted after heart failure 1,750 cases | Too few cases | 19% | 21.3% |
| Readmitted after pneumonia 1,572 cases | Too few cases | 16.5% | 17.3% |
| Readmitted after COPD 240 cases | Too few cases | 20.1% | 20% |
| Readmitted after heart bypass surgery 172 cases | Too few cases | 10% | 11% |
| Readmitted after hip or knee replacement 449 cases | Too few cases | 4.7% | 5.8% |
| Days back in hospital after a heart attack 498 cases | Too few cases | 8.9 days per 100 | — |
| Days back in hospital after heart failure 1,908 cases | Too few cases | -5.8 days per 100 | — |
| Days back in hospital after pneumonia 1,850 cases | Too few cases | 27.7 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 1,197 cases | No different | 13.9 per 1,000 likely 11.1 per 1,000 – 17.5 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 1,174 cases | Worse | 12.8 per 100 likely 11.2 per 100 – 14.7 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 1,174 cases | Better | 3.8 per 100 likely 3 per 100 – 4.8 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 2,580 cases | Better | 0.7 likely 0.6 – 0.8 | — |
1 more measure had too few cases here to report.
Clinicians registered at this address
1,608 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 385 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Anesthesiology | 263 |
| Internal Medicine | 136 |
| Hospitalist | 110 |
| Diagnostic Radiology | 68 |
| Emergency Medicine | 66 |
| Anatomic Pathology & Clinical Pathology | 49 |
| Pediatrics | 48 |
| Acute Care | 43 |
| Specialist | 42 |
| Family | 37 |
| Physician Assistant | 36 |
| Critical Care Medicine | 31 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $40.2M
- 2020 $20.2M
- 2021 $26M
- 2022 $21.3M
- 2023 $20.9M
- 2024 $19.7M
- 2025 $21.9M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $3.4M | 92 |
| Royalties and licensing fees | $2.4M | 15 |
| Speaking, teaching and other services | $580,640 | 37 |
| Space rental and facility fees | $376,710 | 93 |
| Education | $198,834 | 14 |
| Medical devices and supplies on long-term loan | $128,877 | 18 |
| Charitable contributions | $115,500 | 3 |
| Debt forgiveness | $34,179 | 44 |
| Honoraria | $2,488 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Merck Sharp & Dohme LLC | $2.9M | 35 |
| Boston Scientific Corporation | $2.5M | 51 |
| Siemens Medical Solutions USA, Inc. | $2.5M | 11 |
| Edwards Lifesciences Corporation | $2M | 83 |
| Pfizer INC. | $1.3M | 77 |
| Genentech, Inc. | $677,855 | 37 |
| Ultragenyx Pharmaceutical Inc. | $579,166 | 7 |
| Janssen Research & Development, LLC | $516,912 | 68 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma… Merck Sharp & Dohme LLC | $838,431 |
| GTX-102-CL301 Ultragenyx Pharmaceutical Inc. · NCT06617429 | $579,166 |
| A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHR… PFIZER INC. | $565,768 |
| The PROGRESS Trial – Continued Access 2021-01-CAP Edwards Lifesciences Corporation | $545,279 |
| An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Mult… Merck Sharp & Dohme LLC | $426,373 |
| A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Age… Genmab A/S | $416,240 |
| Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With Cardiomyopathy Alnylam Pharmaceuticals Inc. | $372,843 |
| THE ENCIRCLE Trial (#2018-19) Edwards Lifesciences Corporation | $338,845 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Cedars-Sinai Medical Center
Is Cedars-Sinai Medical Center a good hospital?
Cedars-Sinai Medical Center has a CMS overall rating of 5 out of 5 stars. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 14 and worse on 3. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Cedars-Sinai Medical Center?
78% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 1,081 completed HCAHPS surveys.
How long is the wait in the Cedars-Sinai Medical Center emergency room?
Emergency patients spend a median of 5 h 55 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with very high patient volume, like this one, the median is 3 h 21 min. 9% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does Cedars-Sinai Medical Center receive money from drug and device companies?
Drug and device makers reported $21.9M in payments to Cedars-Sinai Medical Center for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.